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Objective: To asses laboratory syphilis testing policies and practices among laboratories in the Americas.
Methods: Laboratory directors or designees from PAHO member countries were invited to participate in a
structured, electronically-delivered survey between March and August, 2014. Data on syphilis tests, algo-
rithms, and quality control (QC) practices were analyzed, focusing on laboratories receiving specimens
from antenatal clinics (ANCs). Results: Surveys were completed by 69 laboratories representing 30 (86%)
countries. Participating laboratories included 36 (52%) national or regional reference labs and 33 (48%)
lower-level laboratories. Most (94%) were public sector facilities and 71% reported existence of a national
algorithm for syphilis testing in pregnancy, usually involving both treponemal and non-treponemal testing
(72%). Less than half (41%) used rapid syphilis tests (RSTs); and only seven laboratories representing ﬁve
countries reported RSTs were included in the national algorithm for pregnant women. Most (83%) labora-
tories serving ANCs reported using some type of QC system; 68% of laboratories reported participation in
external QC. Only 36% of laboratories reported data to national/local surveillance. Half of all laboratories
serving ANC settings reported a stockout of one or more essential supplies during the previous year (medi-
an duration, 30 days). Conclusion: Updating laboratory algorithms, improving testing standards, integrating
data into existing surveillance, and improved procurement and distribution of commodities may be needed
to ensure elimination of MTCT of syphilis in the Americas.
© 2015 Pan American Health Organization; licensee Elsevier. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Syphilis infection during pregnancy is often devastating, resulting in
severe adverse pregnancy outcomes in more than half of untreated
cases [1]. Adverse perinatal outcomes caused by maternal syphilis in-
fection can be prevented through the screening of pregnant women
and by providing prompt treatment for those testing positive [2,3].
Furthermore, syphilis screening and treatment is recognized as one of
the most highly cost-effective public health interventions [4], recom-
mended as part of essential antenatal care (ANC) globally [5]. Despite
this, preventable congenital syphilis infections continue to occur be-
cause pregnant women—especially those who are poor or living in
rural settings—are often not screened according to national guidelines
[6–8]. The most commonly used serologic screening tests for syphilis
require specialized reagents and equipment and trained technicians—ais and STI Unit – CHA//HT, Pan
gton, DC 20037, USA. Tel.: +1
nsee Elsevier. This is an open access alaboratory capacity typically unavailable outside larger hospital or refer-
ence laboratories in most low- and middle-income countries [9].
However, globally, many pregnant women receive ANC at lower-level
facilities without such laboratory capacity [6–8]. To date, little has
been reported in the Americas region regarding the current state of
laboratory-based syphilis testing, including the types of tests available,
algorithms used, or testing quality.
Mother-to-child transmission (MTCT) of syphilis is a signiﬁcant
public health concern worldwide, including in Latin America and the
Caribbean (LAC). In 2008,WHOestimated that, globally, 250 000 infants
were born with congenital syphilis [10]. In the same year, more than
one-third of the estimated 106 500 pregnant women infected with
syphilis in LAC countries were not appropriately treated, resulting in
approximately 33 000 adverse pregnancy outcomes [10,11]. In 2010,
the Pan American Health Organization (PAHO) member countries ap-
proved the Strategy and Plan for Action for this ﬁrst regional initiative
supportingdual elimination, including country-level commitment to re-
ducing incidence of congenital syphilis to 0.5 cases or less (including
stillbirths) per 1000 live births [12]. Reaching the congenital syphilis
elimination goals requires countries to achieve programmatic targetsrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ment (target, 95% treatment ofwomen testingpositive) [11,13]. Region-
al PAHO progress reports have documented consistent increases
in regional syphilis testing coverage: by 2014, at least nine of the 35
PAHO member states had reported data suggesting achievement of
programelimination targets for both syphilis andHIV [14]. Nonetheless,
several countries have continued to lag on coverage of syphilis screen-
ing during pregnancy [14], indicating that reaching the ANC testing
coverage targets continues to be difﬁcult for many countries. New diag-
nostics, such as point-of-care (treponemal) rapid syphilis tests (RSTs),
may be more practical and effective than traditional diagnostics in
ANC settings where rapid treatment is critical [6,15].
The aimof the present survey studywas to assess the syphilis testing
practices of laboratories in PAHO member countries to understand the
syphilis testing algorithms, types of diagnostic tests, and testing prac-
tices and standards currently applied by laboratories in countrieswithin
the region of the Americas.
2. Material and methods
2.1. Survey recruitment, design, and administration
A descriptive, cross-sectional study was conducted among countries
in the Americas to explore syphilis laboratory testing practices in refer-
ence centers and clinical settingswhere syphilis testing typically occurs.
Laboratory directorswere contacted by e-mail and invited to participate
in the survey based on an established contact list with PAHO support.
The sampling goal of the studywas to at least include the national or re-
gional reference laboratory for each country and, if possible, lower-level
laboratories that conducted syphilis testing. There was no limit to the
number of participating laboratories per country.
A structured questionnaire was developed by a panel of technical
laboratory and program experts from PAHO Headquarters and the US
Centers for Disease Control and Prevention (CDC), and was pilot tested
by three laboratory directors in charge of syphilis testing to assure its
utility, validity, and reliability. The ﬁnal questionnaire consisted of the
following sections: respondents’ positions; type of laboratory; syphilis
testing practices, including use of RSTs; barriers to implementation of
RSTs; syphilis testing algorithms used; test volume and turn-around
times; number of staff available to perform syphilis testing; training of
staff; procurement, distribution, stockouts, and funding; other quality
assurance (QA) and quality control (QC) procedures, including external
QA; participation in national, regional, or local surveillance systems; and
perceived needs to improve syphilis testing. In this survey, an RST was
deﬁned as a ﬁnger-prick, whole blood syphilis test that could be per-
formed onsite at a clinical encounter by a trained health provider who
may not be a trained laboratory technician and/or specialist. Respon-
dents were informed that the rapid plasma reagin (RPR) should not
be considered an RST. Laboratory-based tests discussed included non-
treponemal tests (RPR and venereal disease research laboratory
(VDRL) test) and treponemal tests (chemiluminescence immunoassays,
enzyme immunoassay [EIA], ﬂuorescent treponemal antibody absorp-
tion [FTA-ABS], Treponema pallidumhemagglutination assay, Treponema
pallidum particle agglutination assay [TPPA]). Classiﬁcation of LAC sub-
regions (Central America, Caribbean, Andean, and Southern Cone) was
made in the manner of previous PAHO reports [16].
2.2. Survey administration and statistical analysis
The survey was administered electronically between March and
August, 2014, using SurveyMonkey (Palo Alto, CA, USA) via an online
web link. Data were analyzed using SAS version 9.3 (SAS Institute Inc.,
Cary, NC, USA). Descriptive analyses were performed to determine
proportions and percentage of responses between national or re-
gional reference laboratories and local, municipal, district, or hospital
laboratories (i.e. lower-level laboratories) overall and by subregions.Frequencies of laboratory characteristics, syphilis test types, and testing
algorithms were calculated for all laboratories and by laboratory type
(national/regional or lower-level laboratory). Subanalyses of barriers
to RST implementation and stockouts of testing supplies were conduct-
ed only for laboratories receiving specimens from ANC settings and/or
pregnant women.
3. Results
A total of 69 laboratorians from 30 (86%) of the 35 PAHO member
states completed the survey (Table 1). Participating institutions were
fairly equally distributed between larger national or regional reference
laboratories (n = 36, 52%) and lower-level or local laboratories (n =
33, 48%) comprised of maternity hospital laboratories, private or public
hospitals, and other primary or local health clinics. Most (94%) partici-
pating laboratories were public. Of the participating laboratories, 54
(78%) reported receiving specimens for syphilis testing from ANCs.
3.1. Types and use of syphilis tests and testing algorithms applied
Themost common non-treponemal test used was the RPR, reported
by 62% of laboratories (Table 2); 25 (39%) laboratories (46% of national/
regional; 32% of lower-level) reported using only the RPR for non-
treponemal testing, 20 (31%) used only the VDRL test for non-
treponemal testing (30% of national/regional; 32% of lower-level labo-
ratories), and 14 (22%) performed both RPR and VDRL. Four (6%) did
not conduct any non-treponemal syphilis testing. For treponemal sero-
logical tests, FTA-ABS was the most commonly used single test by both
national/regional (47%) and lower-level (33%) laboratories. Twenty-
two laboratories (32%; 25% of national/regional and 39% of lower-
level) reported that they used no laboratory-based treponemal test, al-
though four of these reported using an RST.
Of the 69 reporting laboratories, less than half (41%) reported using
an RST. This was marginally lower compared with laboratories provid-
ing testing for ANCs, of which 46% reported using an RST. Use of RSTs
was slightly less common among lower-level laboratories (36%)
than national/regional laboratories (44%). Among the subregions, the
Caribbean had the lowest use of RSTs (13%) and the Southern Cone
had the highest (57%). The reported reasons for laboratories not using
RSTs varied (Fig. 1), with approximately one-fourth (26%) of the re-
spondents indicating that this was because RSTs were not included in
their national algorithm. Other reasons reported were that the tests
were not included in the procurement system (13%) and that the insti-
tutions were national/reference laboratories that did not provide direct
services to patients (13%). When asked about acceptable settings for
RST implementation, themajority (59%) of respondents thoughtmobile
outreach programs for at-risk populations was an acceptable setting,
followed by ANCs (46%), HIV clinics (49%), sexually transmitted in-
fection (STI) clinics (51%), and primary healthcare clinics (46%). All of
the 25 laboratories conducting RSTs in ANC clinics reported that the
test was conducted by trained laboratory personnel; however, only 3%
of lower-level facilities using RSTs reported that the test was also per-
formed by trained health providers.
Overall, 71% (49) of respondents, representing laboratories from all
30 participating countries reported the existence of a recommended na-
tional algorithm for syphilis testing in pregnant women (Table 3). For
13% of laboratories, respondents reported that there was no such na-
tional algorithm; for the remaining 16%, respondents were unaware of
whether a national algorithm existed for pregnant women. Only seven
laboratories representing ﬁve countries reported their syphilis testing
algorithm for ANC clinics included an RST (ﬁve laboratories used
only an RST, one used an RST with reactive tests conﬁrmed by a non-
treponemal test, and one used a treponemal test conﬁrmed by an RST).
When asked which types of clinical programs their laboratory
supported, 78% (81% of national/regional; 76% of lower-level) reported
receiving samples from ANC programs. Additionally, 77% received
Table 1
Respondent data.a,b
Variables All North Central Caribbean Andean Southern Cone
Number of eligible countries 35 2 8 15 5 5
Response rate 30 (86) 2 (100) 8 (100) 10 (67) 5 (100) 5 (100)
Number of participating laboratories 69 2 22 15 16 14
Type of facility 69 2 22 15 16 14
National/Regional Reference lab 36 (52) 2 (100) 12 (55) 9 (60) 7 (38) 6 (43)
District/Local/Hospital lab 33 (48) 0 (0) 10 (45) 6 (40) 9 (62) 8 (57)
Public laboratory 65 (94) 2 (100) 20 (91) 14 (93) 16 (100) 13 (93)
Private laboratoryc 3 (6) 0 (0) 1 (9) 1 (7) 0 (0) 1 (7)
Participants' job title 69 2 22 15 16 14
Laboratory Supervisor/Manager 31 (45) 2 (100) 7 (32) 8 (53) 8 (50) 6 (43)
Laboratory Technologist 26 (38) 0 (0) 12 (55) 3 (20) 6 (37) 5 (36)
Researcher 1 (1) 0 (0) 0 (0) 1 (7) 0 (0) 0 (0)
Program Manager/Coordinator 11 (16) 0 (0) 3 (13) 3 (20) 2 (13) 3 (21)
a Values are given as number (percentage).
b Based on reference of PAHO’s list of regional countries, Mexico was included in Central, and Brazil included in Southern Cone [14].
c Missing = 1.
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other primary healthcare clinics. The most common algorithm used
for ANC specimens (52%) was a non-treponemal screening test with re-
active tests conﬁrmed by a laboratory-based treponemal test (Table 3).
Approximately half (46%) of laboratories serving ANC programs used
RSTs in some capacity (45% of national/regional; 48% of lower-level).
Fifty-ﬁve percent of laboratories serving HIV programs and 49% of labo-
ratories serving STI programs, comparedwith 4% of laboratories serving
ANC programs, used only RPR or VDRL tests (i.e. non-treponemal tests
without conﬁrmatory testing).
3.2. Quality of syphilis testing and service integration
Respondents reported a median number of ﬁve laboratory staff
(range, 0–30) who performed syphilis testing (any type) at their facili-
ty; and all 69 laboratories reported that the health personnel
performing the tests had received training in syphilis testing. LinkingTable 2
Types of syphilis tests among various laboratories.a
Type of laboratory
Type of test All
(n = 69)
National/ Regional
(n = 36)
Low
(n =
Non-treponemal test (n = 64)b
RPR only 25 (39) 15 (46) 10 (
VDRL only 20 (31) 10 (30) 10 (
Both 14 (22) 4 (12) 10 (
None 4 (6) 3 (9) 1 (
Otherc 1 (2) 1 (3) 0 (
Laboratory-based treponemal test (n = 69)
FTA-ABS only 11 (16) 5 (14) 6 (
TPPA only 5 (7) 4 (11) 1 (
TPHA only 2 (3) 0 (0) 2 (
EIA only 3 (4) 0 (0) 3 (
CIA only 1 (1) 0 (0) 1 (
None 22 (32) 9 (25) 13 (
Multiple treponemal tests 25 (36) 18 (50) 7 (
Rapid treponemal test (n = 54)
Overall
Yes 28 (41) 16 (44) 12 (
No 41 (49) 20 (56) 21 (
ANC settings
Yes 25 (36) 13 (36) 12 (
No 29 (64) 23 (64) 21 (
Abbreviations: ANC, antenatal care; CIA, chemiluminescence immunoassays; EIA, enzyme immu
TPHA, Treponema pallidum hemagglutination; TPPA, Treponema pallidum particle agglutination
a Values are given as number (percentage).
b Missing = 5.
c One laboratory reported using Unheated Serum Reagent.syphilis testing with HIV testing in training programs was reported by
34% of all laboratories and by 39% of those who processed specimens
from ANC programs.
Overall, 80% of laboratories reported using some sort of a standard
QA/QC procedure, including 83% of laboratories serving ANC clinics;
92% of national/regional laboratories and 67% of lower-level laborato-
ries reported they had QA/QC programs. Most laboratories (81%) per-
formed daily serologic testing using controls (87% of laboratories
serving ANCs). Somewhat fewer laboratories (68%; 83% of national/
regional; 52% of lower-level) reported participation in an external QA
program at least annually. Less than half (49%) reported conducting
routine on-site observations of laboratory testing performed in the lab-
oratories. Only 13 countries (out of 30) reported having national proﬁ-
ciency testing programs.
Of the 69 participating laboratories, 48% could provide syphilis test-
ing results within a day, whereas 4% of surveyed laboratories required
more than seven days. Among these, 2% were laboratories receivingRegion
er-level
33)
North
(n = 2)
Central
(n = 22)
Caribbean
(n = 15)
Andean
(n = 16)
Southern Cone
(n = 14)
32) 1 (50) 8 (44) 9 (60) 7 (47) 0 (0)
32) 0 (0) 7 (39) 2 (13) 2 (13) 9 (64)
32) 0 (0) 29 (11) 3 (20) 5 (33) 4 (29)
4) 1 (50) 0 (0) 1 (7) 1 (7) 1 (7)
0) 0 (0) 1 (6) 0 (0) 0 (0) 0 (0)
18) 0 (0) 4 (18) 1 (6) 3 (19) 3 (22)
3) 0 (0) 1 (5) 3 (18) 1 (6) 0 (0)
6) 0 (0) 1 (5) 0 (0) 0 (0) 1 (7)
9) 0(0) 1 (5) 1 (6) 0 (0) 1 (7)
3) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
39) 0 (0) 10 (44) 6 (42) 5 (30) 1 (7)
22) 2 (100) 4 (18) 4 (28) 7 (45) 8 (57)
36) 1 (50) 9 (41) 2 (13) 8 (50) 8 (57)
64) 1 (50) 13 (49) 13 (87) 8 (50) 6 (43)
36) 0 (0) 9 (41) 2 (13) 7 (44) 7 (50)
64) 2 (100) 13 (59) 13 (87) 9 (56) 7 (50)
noassay; FTA-ABS, ﬂuorescent treponemal antibody absorption; RPR, rapid plasma reagin;
assay; VDRL, venereal disease research laboratory.
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Fig. 1.Reasons for not using rapid syphilis tests reported by laboratories. Note: Rapid testswere not performed by41 institutions, including 20national/regional laboratories and 21 lower-
level laboratories.
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The 54 laboratories receiving samples from ANC clinics reported that
they tested a median of 327 samples (range, 1–43 000) per month
(national/regional laboratories median, 238; range, 3–43 000; lower-
level laboratories median, 550; range, 1–40 000). The turn-around
times for test results were relatively rapid (median, 12 hours; range,
1–168 hours), with only one institution reporting that testing required
more than seven days after receipt of the sample. For surveillance
reporting, 36% of laboratories reported data to a national, state, or pro-
vincial communicable disease or maternal and child health surveillance
program (including HIV). When asked about funding sources, 43% of
laboratories reported receiving funding from a national STI program or
integrated STI/HIV program in their countries, whereas 29% were
funded by local provincial programs and 26%by a national HIV program.
Overall, half of all laboratories receiving specimens from ANC set-
tings reported a stockout of oneormore of the essential supplies needed
for syphilis testing during the previous year (Table 4). During the
12 months preceding the survey, at least one stockout was reported
by 55% of laboratories performing the VDRL test, 46% of laboratories
performing EIA, and 30% of the laboratories conducting the RPR test.Table 3
Syphilis testing algorithms used for pregnant women reported by all laboratories serving anten
icine programs (STI).a
Reported syphilis testing algorithms
RPR or VDRL with ALL tests followed by a laboratory-based treponemal test (e.g. TPHA, TP
RPR or VDRL with REACTIVE tests followed by a laboratory-based treponemal testing (e.g.
RPR or VDRL with reactive tests followed by a rapid treponemal test
RPR or VDRL only
Laboratory-based treponemal test (TPPA, FTA-ABS, EIA, CIA) with reactive tests followed b
Rapid treponemal test with reactive tests followed by RPR or VDRL
Laboratory-based treponemal test only (e.g. TPHA, TPPA, FTA-ABS, EIA, CIA)
Rapid treponemal test only
Other
No algorithm or don’t know
Abbreviations: CIA, chemiluminescence immunoassays; EIA, enzyme immunoassay; FTA-ABS,
pallidum hemagglutination; TPPA, Treponema pallidum particle agglutination assay; VDRL, vene
a Values are given as number (percentage).Additionally, 26% of laboratories conducting RPR tests reported
stockouts of the RPR cards. Other essential supplies often unavailable
were pipette tips (14%), gloves (17%), dressing gowns (13%), and glass
syringes. Of note, there were many instances of missing data (i.e. no re-
sponse to questions about stockouts), therefore, the actual rates may
have been much higher. For example, among respondent laboratories
conducting the RPR test, 10 out of 14 (71%) experienced shortage of
RPR reagents, 6 out of 9 (67%) for VDRL reagents, and 6 out of 8 (75%)
for EIA reagents.
4. Discussion
The results of this survey of syphilis testing policies and practices
among laboratories in the Americas region included data from 30
(86%) member states. Some areas of adequate capacity were identiﬁed:
all 30 countries reported having national or regional reference laborato-
ry capacity for syphilis testing. Additionally, at least one laboratory from
each of the 30 reporting countries indicated the existence of a national
algorithm for syphilis testing in ANC services. All responding laborato-
ries had available staff trained in syphilis testing and most reportedatal clinics (ANC), HIV programs (HIV), sexually transmitted infection/genitourinarymed-
ANC
(n = 54)
HIV
(n = 47)
STI
(n = 53)
PA, FTA-ABS, EIA, CIA) 5 (9) 1 (2) 2 (4)
TPHA, TPPA, FTA-ABS, EIA, CIA) 28 (52) 5 (11) 5 (9)
1 (2) 1 (2) 4 (8)
2 (4) 26 (55) 26 (49)
y an RPR or VDRL 4 (7) 1 (2) 0 (0)
1 (2) 0 (0) 0 (0)
0 (0) 2 (4) 2 (4)
5 (9) 6 (13) 8 (15)
4 (7) 2 (4) 1 (2)
4 (7) 3 (6) 5 (9)
ﬂuorescent treponemal antibody absorption; RPR, rapid plasma reagin; TPHA, Treponema
real disease research laboratory.
Table 4
Proportion of laboratories supporting antenatal services (n = 54) with stockouts of re-
agents or supplies during the previous year.a
Type of reagent or supply Stockout
Yes No Don’t know/not
reported
Reagent
RPR (n = 33) 10 (30) 4 (12) 19 (58)
VDRL (n = 11) 6 (55) 3 (27) 2 (18)
TPPA (n = 13) 3 (23) 3 (23) 7 (54)
TPHA (n = 17) 3 (18) 3 (18) 11 (64)
FTA-ABS (n = 24) 5 (21) 1 (4) 18 (75)
EIA (n = 13) 6 (46) 2 (15) 5 (39)
CIA (n = 2) 1 (50) 0 (0) 1 (50)
Rapid treponemalb (n = 25) 5 (20) 2 (8) 18 (72)
Supplies
RPR cards (n = 33) 8 (24) 23 (70) 2 (6)
Pipettes (n = 54) 7 (13) 44 (81) 3 (6)
Gloves (n = 54) 9 (17) 43 (80) 2 (3)
Other (n = 54) 5 (9) 35 (65) 14 (26)
At least one item stockout (n = 54) 27 (50) 27 (50) 0 (0)
Abbreviations: CIA, chemiluminescence immunoassays; EIA, enzyme immunoassay; FTA-
ABS, ﬂuorescent treponemal antibody absorption; RPR, rapid plasma reagin; TPHA, Trepo-
nema pallidum hemagglutination; TPPA, Treponema pallidum particle agglutination assay;
VDRL, venereal disease research laboratory.
a Values are given as number (percentage).
b Test kits or buffer.
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cedures and daily controls). The turn-around times reported by the lab-
oratories tended to be short.
The survey results also identiﬁed several service gaps and areas of
concern. Less than half of the laboratories used RSTs, some to conﬁrm
positive non-treponemal test results, but most (including lower-level
clinics where RSTs are most useful) within a traditional testing algo-
rithm (non-treponemal test followed by a laboratory-based treponemal
conﬁrmatory test). Further, a handful of national or regional laborato-
ries were using either a treponemal or a non-treponemal test alone,
limiting the diagnostic accuracy of their syphilis test results. Additional-
ly, of the laboratories using laboratory-based treponemal tests, many
continued to use the FTA-ABS test despite the more cost-effective, less
subjective, and higher-throughput consuming alternative tests avail-
able (e.g. TPPA, EIAs).
Relatively few laboratories serving lower-level health facilities were
using RSTs in ANC settings, despite these greatly simplifying procedures
and improving services in such settings.Most laboratories reported that
testing was performed primarily by laboratory staff and not by health
providers. The WHO promotes a qualitative non-treponemal screening
test with conﬁrmatory rapid treponemal tests as an efﬁcient strategy
in ANC clinics connected to laboratories [17]. In ANC settings without
laboratories, a rapid treponemal screening test performed by a health
provider could allow syphilis-infected women to be identiﬁed and a
ﬁrst dose of penicillin to be administered at the clinic visit, thus ensuring
prompt treatment of the fetus [17]. In these cases, sending out a blood
sample to a laboratory for a non-treponemal test would support the
syphilis diagnosis and the provision of additional treatment for the
woman and her partner. This approach would be more cost-effective
and have a higher efﬁcacy in protecting the fetus against adverse out-
comes [18] while minimizing the risks of syphilis complications for
both the patient and her sexual partner [19].
Themost commonly reported reason for the lack of RST usewas that
tests were not included in national algorithms, suggesting an opportu-
nity for updating national and/or regional guidance [20]. Additional rea-
sons included RSTs not yet forming part of the procurement systems
and QA protocols not having been developed; these barriers can all be
addressed through national programs. Very few respondents indicated
that these tests were unacceptable or that cost was prohibitive.Although all laboratories reported using some type of QA strategy,
most were primarily focused on basic QC (e.g. using daily controls and
standard operating procedures) and training. Additionally, half of all
laboratories reported a stockout (average 30 days) of at least one essen-
tial item required for syphilis testing during the previous year, suggest-
ing that several country-level procurement systems are inadequate.
Among the essential items reported as unavailable were pipettes,
gloves, and RPR cards—all of which are basic items. Given these ﬁndings,
PAHO is currently workingwith partners to explore potential means for
regional support around QA and procurement systems. This may entail
partnering with other agencies, e.g. theWHO/PAHO Collaborating Cen-
tre at CDCon external quality control of syphilis testing orwith Brazil on
south-to-south technical support [21].
The present study has some limitations. Although there was a high
response rate among PAHO member states, many of the reporting
laboratories were national or regional reference laboratories and their
responses may not reﬂect the experiences of laboratories providing
services at lower-level health facilities where ANC services are typically
offered. Further, the participating lower-level laboratories may not
be representative of similar laboratories in their countries. More-
over, the survey respondents (laboratory staff) may not have been fa-
miliar with details regarding speciﬁc questions on program issues (e.g.
turnaround times for test results or whether other health providers of-
fered syphilis testing) or national policy (e.g. the algorithms reported
may not be the actual algorithms used in the national strategies).
Despite these limitations, this is the ﬁrst situational analysis addressing
syphilis testing practices in the Americas, providing important data
on the current syphilis testing practices and perceived needs of the re-
gion’s laboratories.
These survey results should encourage countries toworkwith PAHO
and its partners in the areas identiﬁed as gaps, such as ensuring quality
of testing through external QA or other strategies and procurement of
essential supplies to help limit stockouts and reduce program costs. In
addition, it is hoped that these results will lead to more in-depth
study in areas such as operational research on the causes of stockouts
and on how speciﬁc program changes (e.g. adoption of new algorithms,
use of RSTs, bulk procurement options, decentralization of services, task
shifting) actually affect the coverage of syphilis screening and treatment
in ANC and other clinical services. Such ﬁeld studies, even if conducted
by only one or a few countries, could provide better evidence of beneﬁt
to other countries in the region.
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